Drug Approval | November 19, 2022
Eugia Pharma receives USFDA approval for Amphotericin B Liposome for Injection
The product is expected to be launched by Q4 FY23.
The product is expected to be launched by Q4 FY23.
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
Domestic business was up 41.9% YoY and 27.7% QoQ
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Subscribe To Our Newsletter & Stay Updated
